Makes and sells Ayurvedic and herbal healthcare products in two streams — human healthcare (45% of revenue) and veterinary/animal healthcare (55%) — across a portfolio of roughly 300 formulations from a manufacturing facility in Himatnagar, Gujarat. Revenue of ₹73.13 Cr in FY26 came from distribution across more than 15 Indian states and from exports to 8 countries including UAE, Kuwait, Iraq, Qatar, Nepal, Bangladesh, Mauritius, Yemen and Sudan, with export revenue at ₹6 Cr (up 164% YoY). Distribution is being expanded through government procurement channels (state schemes, CSD, CGHS, KPKB) and a sales team that the company targets to double from about 80 people in the next two years. Materials (raw herbs, packaging and formulations inputs) are the dominant cost, eating 76% of revenue, with employee cost at 2.5% and other operating expenses at 4.1%. A second manufacturing facility near Ahmedabad (capex of ₹12-15 Cr, land already acquired for ₹2.5 Cr) is set to start installations from CY2027, and management has guided to an FY30 revenue target of ₹200 Cr. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Veterinary / animal healthcare products (55%), Human healthcare products (45%). Asset-light Ayurvedic formulations maker, zero-debt, expanding capacity and distribution
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 40 | 51 | 73 |
| EBITDA (ex other income) | — | — | — |
| margin % | — | — | — |
| Owners' profit | — | — | — |
| EPS, as reported (₹) | 5.36 | 6.26 | 6.58 |
| ROE % · ROCE % | — · 22.9 | — · 22.4 | — · 16.0 |
| Debt / equity (x) | — | — | — |
| Cash from operations | (2) | 5 | (12) |
| Capex | — | (3) | (2) |
| ₹ crore | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 19 | 21 | 24 | 27 | 33 | 40 |
| Profit before tax | 4 | 4 | 5 | 5 | 6 | 6 |
| Net profit | — | — | — | — | — | — |
| EPS (₹) | 2.68 | 2.70 | 3.06 | 3.20 | 3.89 | 2.69 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Shelter Pharma fixes 19th AGM on September 29, 2026 | compliance | minimal | — | — |
| 4 Sept 2026 · 19th AGM on Sep 29, 2026; RPTs and director regularization on agenda | board shareholder meetings | low | — | — |
| 4 Sept 2026 · 19th Annual Report for FY 2025-26 submitted to BSE | compliance | low | — | — |
| 1 Sept 2026 · Board outcome: AGM on Sep 29, new Independent Director appointed | management changes | medium | — | — |
| 1 Sept 2026 · Vinita Gadhavi regularized as Non-Executive Independent Director | management changes | medium | — | — |
| 1 Sept 2026 · Board approves director regularization, related party deals, fixes AGM on Sept 29 | management changes | medium | — | — |
| 25 Aug 2026 · Shelter Pharma dispatches USD 139,200 export order to Sudan | business updates | medium | — | — |
| 24 Aug 2026 · Shelter Pharma completes USD 144,000 export order to Sudan | business updates | medium | — | — |
| 21 Aug 2026 · New Product Launch: SHELTIDIN DS Cough Spray | business updates | medium | — | — |
| 20 Aug 2026 · Shelter Pharma completes USD 12,285 export order to Bangladesh | business updates | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| LAURUS LABS LIMITED |
| 1,06,375 |
| 97.2 |
| 19.59 |
| 59.3 |
| 16.4 |
| 17.2 |
| 7.2 |
| 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 2.4 | 28.9 | 4 of 169 | 98% |
| ROCE | 15.8 | 10.8 | 56 of 183 | 70% |
| Revenue growth | 92.4 | 16.3 | 10 of 161 | 94% |
| Market cap | 51 | 839 | 148 of 182 | 19% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
